[go: up one dir, main page]

CL2008002417A1 - Forma solida vitrea de ester metilico de acido 2-ciano-3,12-dioxoleano-1,9(11)-dien-28-oico; metodo de preparacion; composicion farmaceutica; forma cristalina de solvato de dimetanol de 2-ciano-3,12-dioxoleano-1,9(11)-dien-28-oico, y uso para tratar una condicion inflamatoria - Google Patents

Forma solida vitrea de ester metilico de acido 2-ciano-3,12-dioxoleano-1,9(11)-dien-28-oico; metodo de preparacion; composicion farmaceutica; forma cristalina de solvato de dimetanol de 2-ciano-3,12-dioxoleano-1,9(11)-dien-28-oico, y uso para tratar una condicion inflamatoria

Info

Publication number
CL2008002417A1
CL2008002417A1 CL2008002417A CL2008002417A CL2008002417A1 CL 2008002417 A1 CL2008002417 A1 CL 2008002417A1 CL 2008002417 A CL2008002417 A CL 2008002417A CL 2008002417 A CL2008002417 A CL 2008002417A CL 2008002417 A1 CL2008002417 A1 CL 2008002417A1
Authority
CL
Chile
Prior art keywords
diene
cyano
oic
dioxoleano
pharmaceutical composition
Prior art date
Application number
CL2008002417A
Other languages
English (en)
Inventor
John Walling
Stephan D Parent
David T Robert M Kral Jonaitis Jr
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of CL2008002417A1 publication Critical patent/CL2008002417A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Glass Compositions (AREA)

Abstract

Forma sólida vitrea de 2-ciano-3,12-dioxoleano-1,9(11)-dien-28-oato de metilo (ester metilico de cddo), composición farmacéutica que contenga este compuesto y su uso para una condición cancerosa.
CL2008002417A 2007-08-15 2008-08-14 Forma solida vitrea de ester metilico de acido 2-ciano-3,12-dioxoleano-1,9(11)-dien-28-oico; metodo de preparacion; composicion farmaceutica; forma cristalina de solvato de dimetanol de 2-ciano-3,12-dioxoleano-1,9(11)-dien-28-oico, y uso para tratar una condicion inflamatoria CL2008002417A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95593907P 2007-08-15 2007-08-15

Publications (1)

Publication Number Publication Date
CL2008002417A1 true CL2008002417A1 (es) 2009-03-27

Family

ID=40351005

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002417A CL2008002417A1 (es) 2007-08-15 2008-08-14 Forma solida vitrea de ester metilico de acido 2-ciano-3,12-dioxoleano-1,9(11)-dien-28-oico; metodo de preparacion; composicion farmaceutica; forma cristalina de solvato de dimetanol de 2-ciano-3,12-dioxoleano-1,9(11)-dien-28-oico, y uso para tratar una condicion inflamatoria

Country Status (28)

Country Link
US (3) US8088824B2 (es)
EP (2) EP2187741B1 (es)
JP (4) JP5005812B2 (es)
KR (2) KR101481764B1 (es)
CN (2) CN103254267B (es)
AR (2) AR073155A1 (es)
AT (1) ATE549035T1 (es)
AU (1) AU2008287388B2 (es)
BR (1) BRPI0815540A8 (es)
CA (2) CA2696330C (es)
CL (1) CL2008002417A1 (es)
CY (2) CY1112864T1 (es)
DK (2) DK2450057T3 (es)
EA (2) EA023550B1 (es)
ES (2) ES2602978T3 (es)
HR (2) HRP20120350T1 (es)
HU (1) HUE031866T2 (es)
IL (2) IL203824A (es)
LT (1) LT2450057T (es)
MX (1) MX2010001628A (es)
NZ (1) NZ583269A (es)
PL (2) PL2187741T3 (es)
PT (2) PT2187741E (es)
SG (2) SG10201504650VA (es)
SI (2) SI2187741T1 (es)
TW (2) TWI486357B (es)
WO (1) WO2009023232A1 (es)
ZA (1) ZA201001066B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
CA2472581C (en) 2002-01-15 2012-06-26 Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
US8299046B2 (en) 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
WO2008064133A1 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
KR101780382B1 (ko) * 2008-01-11 2017-10-10 리타 파마슈티컬스 잉크. 합성 트리테르페노이드 및 질병 치료시의 사용 방법
RS58392B1 (sr) 2008-04-18 2019-04-30 Reata Pharmaceuticals Inc Antioksidantni modulatori inflamacije: derivati oleanoličke kiseline sa amino i drugim modifikacijama na c-17
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
RS55631B1 (sr) 2008-04-18 2017-06-30 Reata Pharmaceuticals Inc Antioksidansni modulatori upale: c-17 homologisani derivati oleanolinske kiseline
CN102164941B (zh) 2008-04-18 2015-05-27 里亚塔医药公司 抗氧化剂炎症调节剂:具有饱和c环的齐墩果酸衍生物
CN103588678A (zh) 2008-04-18 2014-02-19 里亚塔医药公司 包含抗炎症药效团的化合物以及使用方法
AU2009274037B2 (en) 2008-07-22 2015-07-09 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
MX2011008344A (es) * 2009-02-13 2011-09-29 Reata Pharmaceuticals Inc Composiciones de dosis orales de liberacion retardada que contiene bardoloxona-metilo (cddo-me) amorfo.
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
EP2536285B1 (en) 2010-02-18 2018-04-25 vTv Therapeutics LLC Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
AU2011240690C1 (en) 2010-04-12 2014-11-06 Reata Pharmaceuticals Holdings, LLC Method of treating obesity using antioxidant inflammation modulators
CA2822071C (en) 2010-12-17 2019-07-16 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
PL2683731T3 (pl) 2011-03-11 2019-09-30 Reata Pharmaceuticals, Inc. C4-monometylowe pochodne triterpenoidów i sposoby ich zastosowania
CN103156861B (zh) * 2011-12-08 2015-11-25 陈丽梅 齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用
WO2013163344A1 (en) 2012-04-27 2013-10-31 Reata Pharmaceuticals, Inc. 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
AU2013312106B2 (en) 2012-09-10 2018-03-08 Reata Pharmaceuticals, Inc. C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
CA2884400A1 (en) * 2012-09-10 2014-03-13 Abbvie Inc. Glycyrrhetinic acid derivatives and methods of use thereof
KR101545068B1 (ko) 2012-09-28 2015-08-17 베이징 즈지엔진루이 셩우이야오 커지 요우시엔공스 Ｃｄｄｏ 에틸 에스테르의 다형체 및 이의 용도
CN102887936A (zh) * 2012-10-24 2013-01-23 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型
CN102875634B (zh) * 2012-10-24 2014-08-20 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型
JP6328102B2 (ja) 2013-03-19 2018-05-23 第一三共株式会社 テルペノイド誘導体
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之２，２－二氟丙醯胺衍生物、其多晶形及其使用方法
CN112870202A (zh) 2013-08-23 2021-06-01 里亚塔医药公司 使用甲基巴多索隆或其类似物治疗和预防肾病的方法
US9896475B2 (en) 2014-08-26 2018-02-20 Trustees Of Dartmouth College Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
US10189791B2 (en) 2014-08-26 2019-01-29 Trustees Of Dartmouth College Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
US10208082B2 (en) 2014-09-10 2019-02-19 Daiichi Sankyo Company, Limited Sustained-release pharmaceutical composition for treatment and prevention of eye disease
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
US11591302B2 (en) 2014-12-19 2023-02-28 Geistlich Pharm A Ag Processes for preparing oxathiazin-like compounds
ES2907592T3 (es) 2014-12-19 2022-04-25 Geistlich Pharma Ag Procesos para preparar compuestos de tipo oxatiazina
JP6748652B2 (ja) 2015-02-12 2020-09-02 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化性炎症調節剤としてのイミダゾリル三環式エノン
RS60411B1 (sr) * 2015-07-02 2020-07-31 Acerta Pharma Bv Čvrsti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida
NZ741082A (en) 2015-09-23 2023-06-30 Reata Pharmaceuticals Inc C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
MX2019005401A (es) 2016-11-08 2019-08-05 Reata Pharmaceuticals Inc Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma.
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
EP3652193A1 (en) 2017-07-13 2020-05-20 Pliva Hrvatska D.O.O. New crystalline polymorphs of bardoxolone methyl
ES2967689T3 (es) 2018-04-06 2024-05-03 Capsugel Belgium Nv Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)]
CA3103726A1 (en) 2018-06-15 2019-12-19 Reata Pharmaceuticals, Inc. Pyrazole and imidazole compounds for inhibition of il-17 and rorgamma
EP3810141A1 (en) 2018-06-20 2021-04-28 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
CN113164436A (zh) 2018-11-27 2021-07-23 协和麒麟株式会社 药物组合物
CA3144603C (en) 2019-07-19 2025-10-21 Reata Pharmaceuticals, Inc. C17 Polar Substitution Heteroaromatic Synthetic Triterpenoids and Their Methods of Use
AU2021273460A1 (en) 2020-05-09 2022-12-08 Reata Pharmaceuticals Holdings, LLC Methods of treating covid-19 using bardoxolone methyl or analogs thereof
US12059419B2 (en) 2020-10-16 2024-08-13 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
EP4259155A1 (en) 2020-12-11 2023-10-18 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1317599C (en) * 1986-03-26 1993-05-11 Yukio Nezu 1,2,6-triphenyl-4(1h)-pyridinone derivatives, production and uses thereof
JPH01273020A (ja) * 1988-04-26 1989-10-31 Toray Ind Inc 有機非線形光学材料
US5064823A (en) 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
JP2876144B2 (ja) * 1990-03-23 1999-03-31 東洋フアルマー株式会社 ３―フェニルクマリン―７―イルオキシ酢酸誘導体とその製法及び用途
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
US20050276836A1 (en) 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6890946B2 (en) * 1999-12-23 2005-05-10 Indiana University Research And Technology Corporation Use of parthenolide to inhibit cancer
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
CA2430454A1 (en) * 2000-11-28 2002-06-20 Board Of Regents, The University Of Texas System Cddo-compounds and combination therapies thereof
JP2006515859A (ja) * 2002-05-13 2006-06-08 トラスティーズ オブ ダートマス カレッジ 阻害剤およびその使用法
JP3618341B2 (ja) * 2003-04-15 2005-02-09 山之内製薬株式会社 臭化物及びその結晶
FR2861299B1 (fr) * 2003-10-28 2006-01-27 Pf Medicament Compositions pharmaceutiques a base de derives d'idasoxan sous formes polymorphes
CN100419534C (zh) 2003-12-08 2008-09-17 索尼株式会社 液晶显示设备和背光调节方法
US20060167097A1 (en) * 2004-04-16 2006-07-27 Cheppail Ramachandran Compositions and uses of Amooranin compounds
AU2006249847B2 (en) * 2005-05-23 2012-12-20 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
DE102005041613A1 (de) 2005-09-01 2007-03-08 Ergonex Pharma Gmbh Pharmazeutische Zusammensetzungen zur Behandlung von Karzinoid-Syndrom
ES2617002T3 (es) 2005-12-12 2017-06-15 Mosamedix B.V. Derivados de anexina adecuados para la prefocalización en terapia y diagnóstico
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester

Also Published As

Publication number Publication date
US20120071684A1 (en) 2012-03-22
HK1143537A1 (en) 2011-01-07
DK2450057T3 (en) 2016-12-19
KR101481764B1 (ko) 2015-01-13
SI2450057T1 (sl) 2017-01-31
CY1118329T1 (el) 2017-06-28
JP2015164939A (ja) 2015-09-17
TWI486357B (zh) 2015-06-01
MX2010001628A (es) 2010-06-02
US20090048204A1 (en) 2009-02-19
EP2187741A1 (en) 2010-05-26
JP5005812B2 (ja) 2012-08-22
EP2450057B1 (en) 2016-09-28
JP2010536754A (ja) 2010-12-02
NZ583269A (en) 2012-03-30
AU2008287388B2 (en) 2014-11-06
PL2450057T3 (pl) 2017-02-28
TW201402597A (zh) 2014-01-16
KR101544766B1 (ko) 2015-08-17
EP2187741A4 (en) 2010-08-25
EA023550B1 (ru) 2016-06-30
CA2696330C (en) 2015-03-24
US20120330050A1 (en) 2012-12-27
EA201070149A1 (ru) 2010-08-30
US8088824B2 (en) 2012-01-03
WO2009023232A1 (en) 2009-02-19
SI2187741T1 (sl) 2012-07-31
TWI419899B (zh) 2013-12-21
ES2382571T3 (es) 2012-06-11
BRPI0815540A8 (pt) 2023-04-11
CY1112864T1 (el) 2016-04-13
SG10201504650VA (en) 2015-07-30
HRP20120350T1 (hr) 2012-05-31
DK2187741T3 (da) 2012-04-16
SG177905A1 (en) 2012-02-28
JP2012188438A (ja) 2012-10-04
PT2187741E (pt) 2012-06-21
EA018704B1 (ru) 2013-10-30
EP2187741B1 (en) 2012-03-14
ES2602978T3 (es) 2017-02-23
KR20140024063A (ko) 2014-02-27
LT2450057T (lt) 2016-12-27
CN101820758A (zh) 2010-09-01
HUE031866T2 (en) 2017-08-28
AU2008287388A1 (en) 2009-02-19
HRP20161503T1 (hr) 2017-01-13
CA2871864C (en) 2016-05-17
PT2450057T (pt) 2016-12-15
CA2696330A1 (en) 2009-02-19
JP2018009001A (ja) 2018-01-18
ZA201001066B (en) 2010-10-27
IL203824A (en) 2017-04-30
CN103254267B (zh) 2016-03-16
EA201370109A1 (ru) 2014-01-30
CN103254267A (zh) 2013-08-21
EP2450057A1 (en) 2012-05-09
BRPI0815540A2 (pt) 2014-09-30
AR073155A1 (es) 2010-10-20
US8633243B2 (en) 2014-01-21
ATE549035T1 (de) 2012-03-15
KR20100056488A (ko) 2010-05-27
PL2187741T3 (pl) 2012-08-31
CA2871864A1 (en) 2009-02-19
US8309601B2 (en) 2012-11-13
CN101820758B (zh) 2013-03-06
AR119704A2 (es) 2022-01-05
TW200916476A (en) 2009-04-16
IL251419A0 (en) 2017-05-29

Similar Documents

Publication Publication Date Title
CL2008002417A1 (es) Forma solida vitrea de ester metilico de acido 2-ciano-3,12-dioxoleano-1,9(11)-dien-28-oico; metodo de preparacion; composicion farmaceutica; forma cristalina de solvato de dimetanol de 2-ciano-3,12-dioxoleano-1,9(11)-dien-28-oico, y uso para tratar una condicion inflamatoria
UY30320A1 (es) Formas polimorficas de 1-((4-metil-quinazolin-2-il)metil)--3-metil-7-(2-butin-1-il)-8-(3-(r)-amino-piperidin-1-il)-xantina, preparaciones, composiciones de preparacion y aplicaciones de las mismas.
CR20120283A (es) Inhibidor de bromodominio de benzodiazepina
UY32490A (es) Inhibidores de beta-secretasa
UY31774A (es) Compuestos de 2-pirimidin-5- ilcarboxamida sustituidos
ECSP088891A (es) Derivados bicíclicos como inhibidores de cetp
CL2009001066A1 (es) Compuestos derivados del acido ciclopentano carboxilico sustituido; inhibidores del receptor lpa edg2; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de enfermedades cardiovasculares, inflamatorias, metabolicas, renales, pulmonares, oncologicas, inmunologicas y alergias, entre otras.
GT201000211A (es) Procesos e intermediarios para la preparación de derivados de acido 5-bifenil-a-il-2-metilpentanoico
HN2011000874A (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
CR9832A (es) Compuestos de pirimidina amida como inhibidores de pgds
EA201001555A1 (ru) Антиоксидативные модуляторы воспаления: производные олеанолевой кислоты с аминовыми и другими модификациями на с-17
ECSP14004812A (es) Triazolopiridinas sustituidas
DK2346888T3 (da) Fremgangsmåde til fremstilling af som SGLT-inhibitorer anvendelige forbindelser
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
EA201001554A1 (ru) Ингибиторы модуляторов воспаления: производные олеанолевой кислоты, гомологированные с-17
CU20120084A7 (es) Compuestos derivados de triazolopiridina sustituidos como inhibidores de la quinasa mps-1 y compuestos intermediarios para su preparación
MX2010002904A (es) N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv).
UY30082A1 (es) Forma cristalina de 1-(1-metiletil)-4`-((2-fluoro-4-metoxifenil)metil)-5`- metil-1h-pirazol-3`-o-b-d-glucopiranosido, un metodo para su preparacion y el uso de la misma para preparar medicamentos
GT201200158A (es) Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para su uso como principio activo farmacéutico
CR20110458A (es) Compuestos de 3-arilquinazolin-4-ona para combatir plagas de invertebrados
NI201002091A (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato.
MX342212B (es) Inhibidores de neprilisina.
TR201203989T1 (tr) Ksantin oksidaz inhibitörleri olarak etkin olan yeni bileşikler, bunları hazırlamaya yönelik yöntem ve bunları içeren farmasötik bileşim.
CL2008001367A1 (es) Compuestos derivados de heterociclos nitrogenados sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una infeccion bacteriana.
CL2007003491A1 (es) Forma cristalina del acido (3s)-3-[n-(n-(2-tercbutilfenil)oxamil)alaninil]amino-5(23,5,6-tetrafluorofenoxi)-4-oxopentanoico; composicion farmaceutica que comprende a dicho compuesto; y su uso para tratar la fibrosis hepatica.